3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Splenomegaly
1
Primary Myelofibrosis
1
Neoplasm Metastasis
1
Melanoma
1
Leukemia
1
Epidermolysis Bullosa Dystrophica
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Anemia
1
Adenocarcinoma
1
Interventions
Cisplatin
55
Radiotherapy
33
Cetuximab
25
Paclitaxel
23
Carboplatin
23
Radiotherapy, Intensity-Modulated
21
pembrolizumab
19
Docetaxel
17
Fluorouracil
16
Nivolumab
14
Drug Therapy
11
Radiation
9
Erlotinib Hydrochloride
8
Blood Specimen Collection
8
durvalumab
7
Magnetic Resonance Spectroscopy
7
Surveys and Questionnaires
6
atezolizumab
5
Surgical Procedures, Operative
5
Radiosurgery
5
Esophagectomy
5
Chemoradiotherapy
5
olaparib
4
dacomitinib
4
Leucovorin
4
Cyclophosphamide
4
Capecitabine
4
Biopsy
4
Afatinib
4
fludarabine phosphate
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Carcinoma, Squamous Cell
×
ON 01910
×
Clear all
NCT03786237
2026-02-24
Rigosertib for RDEB-SCC
Salzburger Landeskliniken
Phase 1/2
Completed
2 enrolled